Stocks and Investing Stocks and Investing
Fri, October 20, 2017
Thu, October 19, 2017

Alethia Young Maintained (BMRN) at Buy with Increased Target to $124 on, Oct 19th, 2017


Published on 2024-10-25 23:42:46 - WOPRAI, Alethia Young
  Print publication without navigation


Alethia Young of Credit Suisse, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $114 to $124 on, Oct 19th, 2017.

Alethia has made no other calls on BMRN in the last 4 months.



There are 5 other peers that have a rating on BMRN. Out of the 5 peers that are also analyzing BMRN, 2 agree with Alethia's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Kennen MacKay of "RBC Capital" Initiated at Hold and Held Target at $93 on, Friday, September 15th, 2017
  • Vincent Chen of "Bernstein" Initiated at Hold and Held Target at $89 on, Thursday, July 27th, 2017


These are the ratings of the 3 analyists that currently disagree with Alethia


  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $117 on, Friday, October 6th, 2017
  • Christopher Raymond of "Piper Sandler" Initiated at Buy on, Thursday, September 14th, 2017
  • Josh Schimmer of "Evercore ISI Group" Initiated at Buy on, Thursday, August 17th, 2017

Contributing Sources